

# Kim R M Blenman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/511956/publications.pdf>

Version: 2024-02-01

17  
papers

625  
citations

933447

10  
h-index

940533

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1152  
citing authors

#	ARTICLE	IF	CITATIONS
1	KDM5B promotes immune evasion by recruiting SETDB1 to silence retroelements. <i>Nature</i> , 2021, 598, 682-687.	27.8	117
2	Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes and Immunotherapy Outcome in Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2019, 25, 2442-2449.	7.0	106
3	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 17.	5.2	106
4	Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers. , 2020, 8, e001558.		85
5	PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5456-5461.	7.0	60
6	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-“PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5299-5306.	7.0	39
7	Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. <i>Npj Breast Cancer</i> , 2018, 4, 28.	5.2	20
8	A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4839.	3.7	18
9	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2587-2597.	7.0	16
10	Pathology of spontaneous and immunotherapy-induced tumor regression in a murine model of melanoma. <i>Pigment Cell and Melanoma Research</i> , 2019, 32, 448-457.	3.3	13
11	Immune Cell and Cell Cluster Phenotyping, Quantitation, and Visualization Using In Silico Multiplexed Images and Tissue Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2019, 95, 399-410.	1.5	13
12	Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. <i>BMJ Open</i> , 2022, 12, e055735.	1.9	9
13	Quantitative and Spatial Image Analysis of Tumor and Draining Lymph Nodes Using Immunohistochemistry and High-Resolution Multispectral Imaging to Predict Metastasis. <i>Methods in Molecular Biology</i> , 2014, 1102, 601-621.	0.9	7
14	Data File Standard for Flow Cytometry, Version <scp>FCS</scp> 3.2. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 100-102.	1.5	6
15	Comprehensive Analysis of Metabolic Isozyme Targets in Cancer. <i>Cancer Research</i> , 2022, 82, 1698-1711.	0.9	4
16	ISAC Probe Tag Dictionary: Standardized Nomenclature for Detection and Visualization Labels Used in Cytometry and Microscopy Imaging. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 103-106.	1.5	3
17	Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer. <i>Cancer Causes and Control</i> , 2022, 33, 831-841.	1.8	3